Title: Dexmedetomidine as an Adjunctive Sedative in Patients Undergoing Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis

Hazem Abosheaishaa, MD, MSc[1], Abdallfatah Abdallfatah, MS[2*], Abdelmalek Abdelghany, MS[2], Arshia Sethi MD[3], Abdellatif Ismail, MD[4], Doha Mohamed, MS[2], Moataz Aboeldahb, MD[5], Omar Abdelhalim, MD[3], Islam Mohamed, MD[6], Mohammad Bilal, MD[7], Ahmed Y. Azzam, MD, MEng[8], Muhammed Amir Essibayi, MD[8, 9], David J. Altschul[8, 9], Mahmoud Nassar, MD[10]

1- Department of Internal Medicine, Icahn School of Medicine at Mount Sinai / NYC Health + Hospitals, Queens, New York, USA.
2- Faculty of Medicine, October 6 University, 6th of October City, Giza, Egypt.
3- Icahn School of Medicine at Mount Sinai / NYC Health + Hospitals, Queens, New York, USA.
4- University of Maryland Medical Center Midtown Campus, 827 Linden Ave, Baltimore, MD 21201, USA.
5- Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 First St. SW Rochester, MN 55905, USA.
6- Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri School of Medicine, Room CE405, 1 Hospital Dr, Columbia, MO 65201, USA.
7- Division of Gastroenterology and Hepatology, Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA.
8- Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, NY, USA.
9- Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
10- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, USA.

Corresponding Author: *

Abdallfatah Abdallfatah, MS,

Faculty of Medicine,

October 6 University,

6th of October City, Giza, Egypt.

Email Address: Abdallfatahofficial@gmail.com

Abstract:

Introduction: Endoscopic submucosal dissection (ESD) allows for curative en-bloc resection of dysplastic gastrointestinal (GI) tract lesions. However, it is associated with postoperative adverse events (AEs) such as pain, bleeding, and perforation. Dexmedetomidine, an α2-receptor agonist, has emerged as a promising adjunct sedative for ESD under moderate sedation, offering anxiolysis and analgesia. We conducted a systematic review and meta-analysis to evaluate its efficacy and safety for use in ESD.

Methods: A comprehensive systematic search was conducted across multiple databases, including Embase, Medline, Scopus, and Web of Science. Studies that involved ESD utilizing dexmedetomidine as an adjunctive medication in combination with other sedatives, were included. Data extraction and risk of bias assessment were independently performed by two reviewers. Meta-analysis was carried out with RevMan using a random-effects model.

Results: Eight studies were included in the final analysis. Dexmedetomidine showed no significant difference in en-bloc or complete resection rates compared to controls. Sedation and procedure times were similar between the two groups as well. Dexmedetomidine significantly reduced restlessness (OR 0.15, 95% CI:0.07 to 0.29) and increased bradycardia (OR 7.15, 95% CI 3.17 to 16.11) compared to controls. Upon subgroup analysis, Dexmedetomidine plus Propofol, and Dexmedetomidine plus Midazolam, revealed the same findings regarding restlessness and bradycardia compared to controls which confirmed the adjunctive effects of Dexmedetomidine.

Conclusions: Dexmedetomidine as an adjunctive sedative appears safe and effective in ESD, reducing restlessness without significant adverse events. The risk of bradycardia is increased, which may be reflective of reduced physiological stress. Future studies should explore optimal dosing and compare Dexmedetomidine with other sedatives in diverse populations.

Keywords: Endoscopic Submucosal Dissection; Dexmedetomidine; Sedation; Dysplastic GI Lesions

1. Introduction:

Endoscopic tumor resection is one of the most common modalities in GI tumor management. Endoscopic submucosal dissection (ESD) is considered superior to mucosal resection in view of offering complete resection with negative histological margins irrespective of the size of the original lesion [1] Despite these overwhelming advantages, ESD is associated with multiple postoperative complications including bleeding, postoperative perforation, and minor complications like abdominal pain, nausea, vomiting, and stricture which limits its use [2]. post-operative abdominal pain is a debilitating complication associated with ESD which is severely underestimated and results in decreased patient satisfaction and longer hospital stays. Studies show the incidence of postoperative pain in 44.9~62.8% of patients, especially in the early post-operative period necessitating the use of aggressive pain management [3,4].

Dexmedetomidine is a new α2-receptor agonist that has anxiolytic, sedative, and analgesic properties which when used in combination with other anesthetics help lower their dose and also decrease postoperative opioid consumption and pain intensity [5,6]. A study done by Chang et al., also shows a better cardiovascular profile of dexmedetomidine as compared to propofol [7].

In our study, we reviewed the possible benefits of dexmedetomidine as an adjunct sedative perioperatively in patients undergoing ESD for GI adenomas and early-stage neoplastic lesions. We evaluated its efficacy by assessing variables like en-bloc resection, Complete resection, sedation time, procedure time, patient restlessness, and other adverse events.

2. Methods:

2.1. Search Strategy and Data Extraction:

A systematic search of relevant literature was conducted across multiple databases, including Embase, Scopus, Web of Science, Medline/PubMed, and Cochrane, from their inception to February 28, 2024. The search strategy utilized Boolean operators to combine terms related to the population, intervention, and outcomes of interest. The following search strategy was employed: ("endoscopic submucosal dissection" OR "ESD" OR "submucosal dissection") AND ("dexmedetomidine" OR "dexmedetomidine" OR "sedative") (**Appendix 1**). The search strategy aimed to identify studies investigating the use of dexmedetomidine as an adjunctive sedative in endoscopic submucosal dissection procedures. Our research adhered to the recommended guidelines for reporting systematic reviews and meta-analyses. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and Cochrane criteria were followed to ensure transparency and completeness in reporting [8,9].

Two independent reviewers screened titles, abstracts, and full-text articles for inclusion based on predefined eligibility criteria. Any disagreements were resolved through discussion or consultation with a third reviewer. Data extraction was conducted independently by two co-authors using a standardized data extraction form, with

discrepancies resolved through consensus. Extracted data included study characteristics, patient demographics, details of the intervention and comparator, and outcomes of interest.

2.2. Inclusion Criteria and Study Outcomes:

Studies eligible for inclusion in this meta-analysis were those focusing on patients who had gastrointestinal adenomas and early-stage neoplastic lesions eligible for endoscopic submucosal dissection (ESD) treatment. The intervention of interest was the use of dexmedetomidine as an adjunctive medication in combination with other sedatives in submucosal endoscopic dissection. There was no specific comparator for this review. The primary outcome of interest was the en-bloc resection. Secondary outcomes included Complete resection, sedative time, procedure time, restlessness, and different adverse events. Included study designs were randomized controlled trials (RCTs) and observational studies if applicable. Studies not written in English or with inadequate translation, Systematic reviews, Meta-analyses, Case reports, editorials, letters, or conference abstracts without full-text availability, animal studies, or studies conducted on non-human subjects were excluded.

2.3. Risk of Bias Assessment:

The risk of bias and methodological quality of the included studies was assessed independently by two authors. The Cochrane risk-of-bias tool version 2, (ROB 2) was employed for RCTs. For observational studies, we used the Newcastle-Ottawa Scale, any discrepancies were resolved through discussion or consultation with a third reviewer [10].

2.4. Statistical Analysis:

A meta-analysis was conducted using Review Manager 5.4 (Cochrane Collaboration, Copenhagen, The Nordic Cochrane Centre). Given the anticipated heterogeneity in study designs and populations, a random-effects model was utilized. Summary measures were expressed as pooled odds ratios (OR) with corresponding 95% confidence intervals (CI) for proportional variables and mean differences with corresponding 95% CIs for continuous variables. Statistical significance was set at a p-value <0.05. Heterogeneity was assessed using the I2 statistic, with an I2 value of ≥50% indicating significant heterogeneity defined by the Cochrane Handbook for systematic reviews [11].

3. Results:

3.1. Search results:

The initial search retrieved 216 studies, 104 of them underwent title and abstract screening, and 25 full texts were assessed for inclusion. Eight studies were included in our final analysis (**Figure 1**).

3.2. Study and patient characteristics:

A total of 836 patients were included in our meta-analysis. Of the 836 patients, 412 (49.2%) were assigned to the Dexmedetomidine group, whereas 424 (50.7%) were assigned to the placebo group.

The included eight studies' characteristics are displayed in (**Table 1**).

3.3. *Quality of included studies:*

Quality assessment of included studies was assessed using (the Cochrane RoB 2 tool) for Randomized clinical trials. Four studies had a total low risk of bias, and one study had a moderate risk of bias. Another three Cohort studies were assessed using the Newcastle–Ottawa Scale with a low risk of bias (**Appendix 2**).

3.4. *Meta-analysis outcomes:*

1- *En-bloc resection:*

The data from 7 studies were analyzed for En-bloc resection, the odds ratio was 1.45 with a 95% confidence interval (CI) of 0.47 to 4.41 which revealed no significant difference between the two groups (p=0.52) at random effect as shown in **Figure 2**.

2- *Complete resection:*

Three studies reported a complete resection rate, and the odds ratio was 0.62 with a 95% confidence interval (CI) of 0.21 to 1.80 which revealed no significant difference between the two groups (p=0.38) as shown in **Figure 3**.

3- *Sedation time:*

The pooled results from four studies reporting on sedation time revealed that there was no significant difference between the two groups, as shown in **Figure 4** (MD: 6.81, 95% CI: -2.25-15.87; I^2 0%; P=0.14).

4- *Procedure Time:*

Five studies reporting on procedure time revealed that there was no significant difference between the two groups as shown in **Figure 5** (MD: 3.21, 95% CI: -6.32-12.74; I^2 0%; P=0.51).

5- *Restlessness:*

Four studies reported a restlessness rate, the odds ratio was 0.15 with a 95% confidence interval (CI) of 0.07 to 0.29 which revealed a significant difference between the two groups (p<0.00001). as shown in **Figure 6**.

6- *Bradycardia:*

Seven studies reported the bradycardia rate, and the odds ratio was 7.15 with a 95% confidence interval (CI) of 3.17 to 16.11 which revealed a significant difference between the two groups (p<0.00001) as shown in **Figure 7**.

7- Hypoxia:

Four studies reported the Hypoxia rate and the odds ratio was 0.95 with a 95% confidence interval (CI) of 0.38 to 2.36 which revealed no significant difference between the two groups (p=0.91) as shown in **Figure 8**.

8- Hypotension:

Seven studies reported the Hypotension rate and the odds ratio was 2.73 with a 95% confidence interval (CI) of 0.79 to 9.43 which revealed no significant difference between the two groups (p=0.11) as shown in **Figure 9**.

9- Perforation:

Five studies reported the perforation rate and the odds ratio was 0.51 with a 95% confidence interval (CI) of 0.05 to 5.44 which revealed no significant difference between the two groups (p=0.58) as shown in **Figure 10**.

10- Bleeding:

Three studies reported the Bleeding rate, the odds ratio was 0.41 with a 95% confidence interval (CI) of 0.12 to 1.39 which revealed no significant difference between the two groups (p=0.15) .as shown in **Figure 11**.

3.5. Subgroup Analysis Outcomes:

1- Dexmedetomidine + Propofol:

***1.1.** En-bloc resection (Dexmedetomidine + Propofol):*

Two studies reported en-bloc resection rate for Dexmedetomidine in combination with propofol, the odds ratio was 3.09 with a 95% confidence interval (CI) of 0.12 to 78.70 which revealed no significant difference between the two groups (p=0.49) as shown in **Figure 12**.

***1.2.** Complete resection (Dexmedetomidine + Propofol):*

Two studies reported a complete resection rate for Dexmedetomidine in combination with propofol, the odds ratio was 0.72 with a 95% confidence interval (CI) of .23 to 2,24 which revealed no significant difference between the two groups (p=0.57) as shown in **Figure 13**.

***1.3.** Procedure Time (Dexmedetomidine + Propofol):*

Two studies reporting on procedure time for Dexmedetomidine in combination with propofol revealed that there was no significant difference between the two groups as shown in **Figure 14** (MD: -4.05, 95% CI: -27.57-19.47; I^2=63%; P=0.74).

1.4. Restlessness (Dexmedetomidine + Propofol):

Two studies reported Restlessness for Dexmedetomidine in combination with propofol, the odds ratio was 0.14 with a 95% confidence interval (CI) of 0.05 to 0.45 which revealed a significant difference between the two groups (p=0.0009) as shown in **Figure 15**.

1.5. Bradycardia (Dexmedetomidine + Propofol):

Two studies reported Bradycardia for Dexmedetomidine in combination with propofol, the odds ratio was 10.04 with a 95% confidence interval (CI) of 2.92 to 34.54 which revealed a significant difference between the two groups (p=0.0003) as shown in **Figure 16**.

1.6. Hypoxemia (Dexmedetomidine + Propofol):

Two studies reported hypoxemia for Dexmedetomidine in combination with propofol, the odds ratio was 0.28 with a 95% confidence interval (CI) of 0.11 to 0.71 which revealed a significant difference between the two groups (p=0.007) as shown in **Figure 17**.

1.7. Hypotension *(Dexmedetomidine + Propofol):*

Two studies reported Hypotension for Dexmedetomidine in combination with propofol, the odds ratio was 3.83 with a 95% confidence interval (CI) of 1.00 to 14.69 which revealed a significant difference between the two groups (p=0.05) as shown in **Figure 18**.

2- *Dex + Midazolam:*

2.1. En-bloc resection (Dex + Midazolam):

Two studies reported en-bloc resection for Dexmedetomidine in combination with Midazolam, the odds ratio was 1.80 with a 95% confidence interval (CI) of 0.50 to 6.51 which revealed no significant difference between the two groups (p=0.37) .as shown in **Figure 19**.

2.2. Restlessness (Dex + Midazolam):

Two studies reported Restlessness for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.15 with a 95% confidence interval (CI) of 0.06 to 0.35 which revealed a significant difference between the two groups (p < 0.0001) as shown in **Figure 20**.

2.3. Bradycardia (Dex + Midazolam):

Two studies reported Bradycardia for Dexmedetomidine in combination with Midazolam, the odds ratio was 14.97 with a 95% confidence interval (CI) of 2.44 to 91.68 which revealed a significant difference between the two groups (p=0.003) as shown in **Figure 21**.

2.4. Hypoxia (Dex + Midazolam):

Two studies reported Hypoxia for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.80 with a 95% confidence interval (CI) of 0.33 to 1.94 which revealed no significant difference between the two groups (p=0.62) as shown in **Figure 22**.

2.5. Bleeding (Dex + Midazolam):

Two studies reported Bleeding for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.42 with a 95% confidence interval (CI) of 0.11 to 1.60 which revealed no significant difference between the two groups (p=0.20) as shown in **Figure 23**.

2.6. Perforation (Dex + Midazolam):

Two studies reported Perforation for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.24 with a 95% confidence interval (CI) of 0.01 to 4.13 which revealed no significant difference between the two groups (p=0.32) as shown in **Figure 24**.

4. Discussion

Although the debilitating pain associated with ESD warrants aggressive pain management, physicians are hesitant due to the possibility of masking the pain of perforation. This not only causes patient discomfort but also increases the burden on healthcare by prolonging discharge time [2,4]. A study done by Seiichiro et al. shows an increased incidence of metachronous gastric cancer in patients who underwent curative ESD of early gastric cancer [12]. These warrant further endoscopic surveillance and possible repeat ESD. However, poorly managed post-operative pain increases apprehension in patients for further endoscopic procedures. As previously described, a few studies have been done describing the incidence of postoperative pain after ESD but there is no consensus on the management of the said pain. Studies done by Lee and Kim recommend a single dose of dexamethasone or postoperative local bupivacaine and triamcinolone [13,14].

In our study, we found a significant reduction in restlessness and bradycardia associated with dexmedetomidine highlighting its potential as an effective sedative agent for endoscopic procedures. We also observed a statistically significant decrease in tachycardia which could indicate less anxiety and pain thus providing a more comfortable sedative experience for the patients. These properties could be attributed to its selective alpha 2 adrenergic agonist and sympatholytic properties [15]. The non-significant difference found in en bloc resection

rates between dexmedetomidine, and the comparator groups alleviated concerns regarding the influence of the sedation regimen on the technical aspects of the procedure [16].

The subgroup analysis also revealed better outcomes particularly in terms of reduced restlessness and bradycardia, with Dexmedetomidine in combination with Midazolam compared to other combinations. The anxiolytic and amnestic properties of Midazolam, coupled with the sedative and analgesic effects of Dexmedetomidine, may offer superior patient comfort and procedural tolerance. Additionally, considering the favorable safety profile of Midazolam in terms of respiratory depression compared to Propofol, this combination presents a compelling option for optimizing sedation strategies in endoscopic settings [17].

Our review suggests that dexmedetomidine is an effective sedative agent for ESD. Lee et al. [18] on the other hand, compared the outcomes of sedation using dexmedetomidine infusion plus on-demand midazolam versus sedation using midazolam infusion plus on-demand midazolam. They concluded that the sedation effect of dexmedetomidine with midazolam was superior to the sedation effect with midazolam alone. Furthermore, four studies reported sedation time as an outcome, while five studies reported procedure time as an outcome, **Figure 4** and **Figure 5**. The pooled results from these studies showed no statistically significant difference in sedation or procedure time between the dexmedetomidine and the control group. Despite the significant reduction in intraoperative restlessness in the dexmedetomidine group in our review, as mentioned above, this did not translate into a shorter sedation or procedure time, (**Figure 6**).

Nonaka et al. [19] reported a significantly shorter procedure time in the combination group (dexmedetomidine and propofol) compared to the benzodiazepine group; nevertheless, this finding was lost after pooling with other studies in the analysis, as shown in **Figure 5**.

In terms of safety, our findings support the use of dexmedetomidine as an adjunctive agent in procedural sedation for ESD procedures, consistent with previous studies [20,21]. As noted by Candiotti et al. [20], the Dexmedetomidine group demonstrated a higher incidence of bradycardia, as illustrated in **Figure 7**. However, there was no statistically significant increase in the occurrence of other adverse events such as hypoxia, hypotension, bleeding, or perforation. Additionally, Dexmedetomidine's cardiovascular and hemodynamic effects are well-known and are attributed to its strong alpha 2-adrenergic agonist effect and include bradycardia, hypotension, and hypoxia [20-23]. Kim et al. evaluated risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia [23] and found that a long tourniquet time and low baseline heart rate were associated with an increased incidence of bradycardia during procedures under spinal anesthesia. Notably, Alshikaria [24] et al. reported that no serious adverse events were observed in patients in the dexmedetomidine group who experienced bradycardia and that their clinical outcomes were not altered due to it, which is also consistent with previous literature [25,26].

The use of Dexmedetomidine as an adjunctive sedative has shown promising results in our meta-analysis, yet this type of intervention needs further exploration. The included studies in this review have already explored the combination of Dexmedetomidine with the two main sedatives, propofol and midazolam. The results are extraordinary in terms of restlessness and bradycardia incidence, the latter being a good sign of less stress and discomfort during the procedure. Less movements (restlessness) during the ESD procedure leads to more convenient and accurate procedures from the operator. So, this therapy should be explored more to reach the best results possible for the patient. More exploration means more multicenter randomized controlled trials and

observational studies comparing this type of adjunctive therapy with other adjunctive sedatives and even other types of pain management methods, like local anesthesia in the region of intervention, to test this intervention's safety and efficacy to standardize its use during ESD procedures in the near future.

Limitations: To our knowledge, this is the first meta-analysis to assess the safety and efficacy of Dexmedetomidine as an adjunctive sedative after ESD. Additionally, we performed subgroup analysis according to each general therapy. Most included articles (6 out of 8) did not conduct a head-to-head comparison between dexmedetomidine and other agents. Also, the limited number of published clinical trials and the number of patients included in certain subgroups make our evidence and conclusions limited on some outcomes. All of our eight included trials were conducted in eastern Asia, including 5 in Japan, two in Korea, and one in China. Thus, the generalizability of this study results to other regions with different ethnicities and medical environments may be affected. A standardized dosage of dexmedetomidine as an adjuvant sedative has not yet been established, resulting in a wide variety of dexmedetomidine regimens.

5. Conclusions:

In conclusion, our meta-analysis supports the safe use of dexmedetomidine as an adjunctive sedative in ESD procedures. Dexmedetomidine, when combined with other sedatives, appears to reduce restlessness without increasing the risk of hypoxia, hypotension, bleeding, or perforation. The increased risk of bradycardia noted with dexmedetomidine can be perceived as less physiological stress and tachycardia during procedures. However, our findings are limited by the lack of direct comparisons with other sedatives and the predominantly Eastern Asian study populations. Further research, including multicenter trials, is needed to establish optimal dosing regimens and evaluate dexmedetomidine's efficacy compared to other sedatives and pain management methods in diverse patient populations.

6. Declarations:

Conflicts of Interest: N/A.

IRB Approval: N/A.

Funding Source: The project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Ethical Approvals: N/A.

Consent for Participation: N/A.

References:

1. Isomoto H, Shikuwa S, Yamaguchi N, et al.: Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut. 2009, 58:331-336. 10.1136/gut.2008.165381

2. Nishizawa T, Yahagi N: Endoscopic mucosal resection and endoscopic submucosal dissection: technique and new directions. Curr Opin Gastroenterol. 2017, 33:315-319. 10.1097/mog.0000000000000388

3. Luo X, An LX, Chen PS, Chang XL, Li Y: Efficacy of dexmedetomidine on postoperative pain in patients undergoing gastric and esophageal endoscopic submucosal dissection: a study protocol for a randomized controlled prospective trial. Trials. 2022, 23:491. 10.1186/s13063-022-06432-4

4. Kim JW, Jang JY, Park YM, Shim JJ, Chang YW: Clinicopathological characteristics of patients with pain after endoscopic submucosal dissection for gastric epithelial neoplasm. Surg Endosc. 2019, 33:794-801. 10.1007/s00464-018-6345-3

5. Ramsay MA, Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology. 2004, 101:787-790. 10.1097/00000542-200409000-00028

6. Liu Y, Liang F, Liu X, Shao X, Jiang N, Gan X: Dexmedetomidine Reduces Perioperative Opioid Consumption and Postoperative Pain Intensity in Neurosurgery: A Meta-analysis. J Neurosurg Anesthesiol. 2018, 30:146-155. 10.1097/ana.0000000000000403

7. Chang ET, Certal V, Song SA, et al.: Dexmedetomidine versus propofol during drug-induced sleep endoscopy and sedation: a systematic review. Sleep Breath. 2017, 21:727-735. 10.1007/s11325-017-1465-x

8. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010, 8:336-341. 10.1016/j.ijsu.2010.02.007

9. Cumpston M, Li T, Page MJ, et al.: Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019, 10:Ed000142. 10.1002/14651858.Ed000142

10. Sterne JAC, Savović J, Page MJ, et al.: RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019, 366:l4898. 10.1136/bmj.l4898

11. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook-diagnostic-test-accuracy/current

12. Abe S, Oda I, Suzuki H, et al.: Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy. 2015, 47:1113-1118. 10.1055/s-0034-1392484

13. Lee HW, Lee H, Chung H, et al.: The efficacy of single-dose postoperative intravenous dexamethasone for pain relief after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc. 2014, 28:2334-2341. 10.1007/s00464-014-3463-4

14. Kim B, Lee H, Chung H, et al.: The efficacy of topical bupivacaine and triamcinolone acetonide injection in the relief of pain after endoscopic submucosal dissection for gastric neoplasia: a randomized double-blind, placebo-controlled trial. Surg Endosc. 2015, 29:714-722. 10.1007/s00464-014-3730-4

15. Afonso J, Reis F: Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012, 62:118-133. 10.1016/s0034-7094(12)70110-1

16. Dumoulin FL, Hildenbrand R: Endoscopic resection techniques for colorectal neoplasia: Current developments. World J Gastroenterol. 2019, 25:300-307. 10.3748/wjg.v25.i3.300

17. Yoshio T, Ishiyama A, Tsuchida T, et al.: Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma. Esophagus. 2019, 16:285-291. 10.1007/s10388-019-00666-z

18. Lee SP, Sung IK, Kim JH, et al.: Comparison of dexmedetomidine with on-demand midazolam versus midazolam alone for procedural sedation during endoscopic submucosal dissection of gastric tumor. J Dig Dis. 2015, 16:377-384. 10.1111/1751-2980.12254

19. Nonaka T, Inamori M, Miyashita T, et al.: Feasibility of deep sedation with a combination of propofol and dexmedetomidine hydrochloride for esophageal endoscopic submucosal dissection. Dig Endosc. 2016, 28:145-151. 10.1111/den.12559

20. Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY: Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010, 110:47-56. 10.1213/ane.0b013e3181ae0856

21. Riker RR, Shehabi Y, Bokesch PM, et al.: Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. Jama. 2009, 301:489-499. 10.1001/jama.2009.56

22. Bloor BC, Ward DS, Belleville JP, Maze M: Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology. 1992, 77:1134-1142. 10.1097/00000542-199212000-00014

23. Kim HJ, Ahn E: Risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia: A retrospective study. Medicine (Baltimore). 2022, 101:e31306. 10.1097/md.0000000000031306

24. Ashikari K, Nonaka T, Higurashi T, et al.: Efficacy of sedation with dexmedetomidine plus propofol during esophageal endoscopic submucosal dissection. J Gastroenterol Hepatol. 2021, 36:1920-1926. 10.1111/jgh.15417

25. Mason KP, Robinson F, Fontaine P, Prescilla R: Dexmedetomidine offers an option for safe and effective sedation for nuclear medicine imaging in children. Radiology. 2013, 267:911-917. 10.1148/radiol.13121232

26. Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T: Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res. 2009, 30:599-605. 10.1097/BCR.0b013e3181abff90

Figures Legend:

Figure 1: PRISMA flow diagram of the search strategy.

Figure 2: En-bloc resection.

Study or Subgroup	Favours control Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Ashikari 2021	33	33	32	33	11.9%	3.09 [0.12, 78.70]
Iwagami 2023	151	155	126	132	75.0%	1.80 [0.50, 6.51]
Kim 2015	34	36	32	32	13.1%	0.21 [0.01, 4.59]
Kinugasa 2018	40	40	40	40		Not estimable
Lee 2015	40	40	40	40		Not estimable
Nonaka 2016	20	20	20	20		Not estimable
Yoshio 2019	65	65	99	99		Not estimable
Total (95% CI)		389		396	100.0%	1.45 [0.47, 4.41]
Total events	383		389			

Heterogeneity: Tau² = 0.00; Chi² = 1.82, df = 2 (P = 0.40); I² = 0%
Test for overall effect: Z = 0.65 (P = 0.52)

Odds Ratio IV, Random, 95% CI — Favours control | Favours Dexmedetomidine

Figure 3: Complete resection.

Study or Subgroup	Dex as adjunctive Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Ashikari 2021	28	33	29	33	56.8%	0.77 [0.19, 3.18]
Kim 2015	34	36	32	32	12.0%	0.21 [0.01, 4.59]
Nonaka 2016	17	20	18	20	31.2%	0.63 [0.09, 4.24]
Total (95% CI)		89		85	100.0%	0.62 [0.21, 1.80]
Total events	79		79			

Heterogeneity: Tau² = 0.00; Chi² = 0.56, df = 2 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.88 (P = 0.38)

Odds Ratio IV, Random, 95% CI — Favours Control | Favours Dexmedetomidine

Figure 4: Sedation time.

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Ashikari 2021	173.06	198.63	33	210.74	295.72	33	0.6%	-37.68 [-159.22, 83.86]
Kim 2015	42.8	26.7	29	37.6	18.5	30	59.3%	5.20 [-6.56, 16.96]
Luo 2023	107.37	54.68	30	102.16	46.47	30	12.4%	5.21 [-20.47, 30.89]
Yoshio 2019	112.27	62.96	65	100.4	40.07	99	27.7%	11.87 [-5.35, 29.09]
Total (95% CI)			157			192	100.0%	6.81 [-2.25, 15.87]

Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)

Mean Difference IV, Random, 95% CI — Favours Dexmedetomidine | Favours Control

Figure 5: Procedure Time.

Study or Subgroup	Dexmedetomidine Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Ashikari 2021	57.54	33.42	33	51.92	22.12	33	48.6%	5.62 [-8.05, 19.29]
Kinugasa 2018	95.08	74.97	40	92.53	49.98	40	11.6%	2.55 [-25.37, 30.47]
Lee 2015	114.4	74.8	40	100.5	68.5	40	9.2%	13.90 [-17.53, 45.33]
Luo 2023	67.31	49.42	30	58.96	40.86	30	17.2%	8.35 [-14.60, 31.30]
Nonaka 2016	77.49	45.76	20	96.43	38	20	13.4%	-18.94 [-45.01, 7.13]
Total (95% CI)			163			163	100.0%	3.21 [-6.32, 12.74]

Heterogeneity: Tau² = 0.00; Chi² = 3.53, df = 4 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.66 (P = 0.51)

Mean Difference IV, Random, 95% CI — Favours Dexmedetomidine | Favours Control

Figure 6: Restlessness.

Figure 7: Bradycardia.

Figure 8: Hypoxia.

Figure 9: Hypotension.

Figure 10: Perforation.

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Odds Ratio IV, Random, 95% CI
Ashikari 2021	0	33	0	33		Not estimable
Iwagami 2023	0	155	7	132	34.5%	0.05 [0.00, 0.95]
Kinugasa 2018	0	40	0	40		Not estimable
Lee 2015	1	40	1	40	35.4%	1.00 [0.06, 16.56]
Nonaka 2016	1	20	0	20	30.1%	3.15 [0.12, 82.16]
Total (95% CI)		**288**		**265**	**100.0%**	**0.51 [0.05, 5.44]**
Total events	2		8			

Heterogeneity: Tau² = 2.04; Chi² = 3.77, df = 2 (P = 0.15); I² = 47%
Test for overall effect: Z = 0.55 (P = 0.58)

Figure 11: Bleeding.

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Odds Ratio IV, Random, 95% CI
Iwagami 2023	0	155	1	132	14.7%	0.28 [0.01, 6.98]
Lee 2015	3	40	6	40	71.0%	0.46 [0.11, 1.98]
Nonaka 2016	0	20	1	20	14.3%	0.32 [0.01, 8.26]
Total (95% CI)		**215**		**192**	**100.0%**	**0.41 [0.12, 1.39]**
Total events	3		8			

Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 2 (P = 0.95); I² = 0%
Test for overall effect: Z = 1.44 (P = 0.15)

Figure 12: En-bloc resection (Dexmedetomidine + Propofol).

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Odds Ratio IV, Random, 95% CI
Ashikari 2021	33	33	32	33	100.0%	3.09 [0.12, 78.70]
Nonaka 2016	20	20	20	20		Not estimable
Total (95% CI)		**53**		**53**	**100.0%**	**3.09 [0.12, 78.70]**
Total events	53		52			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.49)

Figure 13: Complete resection (Dexmedetomidine + Propofol).

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Odds Ratio IV, Random, 95% CI
Ashikari 2021	28	33	29	33	64.6%	0.77 [0.19, 3.18]
Nonaka 2016	17	20	18	20	35.4%	0.63 [0.09, 4.24]
Total (95% CI)		**53**		**53**	**100.0%**	**0.72 [0.23, 2.24]**
Total events	45		47			

Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.57 (P = 0.57)

Figure 14: Procedure Time (Dexmedetomidine + Propofol).

	Experimental			Control				Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI
Ashikari 2021	57.54	33.42	33	51.92	22.12	33	60.6%	5.62 [-8.05, 19.29]		
Nonaka 2016	77.49	45.76	20	96.43	38	20	39.4%	-18.94 [-45.01, 7.13]		
Total (95% CI)			53			53	100.0%	-4.05 [-27.57, 19.47]		

Heterogeneity: Tau² = 188.81; Chi² = 2.67, df = 1 (P = 0.10); I² = 63%
Test for overall effect: Z = 0.34 (P = 0.74)

-200 -100 0 100 200
Favours Dex+Propofol Favours Control

Figure 15: Restlessness (Dexmedetomidine + Propofol).

	Experimental		Control			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	1	33	9	33	29.1%	0.08 [0.01, 0.70]	
Nonaka 2016	5	20	13	20	70.9%	0.18 [0.05, 0.70]	
Total (95% CI)		53		53	100.0%	0.14 [0.05, 0.45]	
Total events	6		22				

Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 1 (P = 0.55); I² = 0%
Test for overall effect: Z = 3.31 (P = 0.0009)

0.001 0.1 1 10 1000
Favours Dex+Propofol Favours Control

Figure 16: Bradycardia (Dexmedetomidine + Propofol).

	Experimental		Control			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	10	33	1	33	33.8%	13.91 [1.66, 116.41]	
Nonaka 2016	12	20	3	20	66.2%	8.50 [1.86, 38.82]	
Total (95% CI)		53		53	100.0%	10.04 [2.92, 34.54]	
Total events	22		4				

Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 3.66 (P = 0.0003)

0.001 0.1 1 10 1000
Favours Dex+Propofol Favours Control

Figure 17: Hypoxemia (Dexmedetomidine + Propofol).

	Experimental		Control			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	6	33	13	33	69.8%	0.34 [0.11, 1.06]	
Nonaka 2016	2	20	8	20	30.2%	0.17 [0.03, 0.92]	
Total (95% CI)		53		53	100.0%	0.28 [0.11, 0.71]	
Total events	8		21				

Heterogeneity: Tau² = 0.00; Chi² = 0.47, df = 1 (P = 0.49); I² = 0%
Test for overall effect: Z = 2.69 (P = 0.007)

0.001 0.1 1 10 1000
Favours Dex+Propofol Favours Control

Figure 18: Hypotension (Dexmedetomidine + Propofol).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Ashikari 2021	12	33	7	33	57.5%	2.12 [0.71, 6.35]	
Nonaka 2016	12	20	3	20	42.5%	8.50 [1.86, 38.82]	
Total (95% CI)		**53**		**53**	**100.0%**	**3.83 [1.00, 14.69]**	
Total events	24		10				

Heterogeneity: Tau² = 0.51; Chi² = 2.11, df = 1 (P = 0.15); I² = 53%
Test for overall effect: Z = 1.96 (P = 0.05)

Favours Dex+Propofol Favours Control

Figure 19: En-bloc resection (Dex + Midazolam).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Iwagami 2023	151	155	126	132	100.0%	1.80 [0.50, 6.51]	
Lee 2015	40	40	40	40		Not estimable	
Yoshio 2019	65	65	99	99		Not estimable	
Total (95% CI)		**260**		**271**	**100.0%**	**1.80 [0.50, 6.51]**	
Total events	256		265				

Heterogeneity: Not applicable
Test for overall effect: Z = 0.89 (P = 0.37)

Favours control Favours Dex+Midazolam

Figure 20: Restlessness (Dex + Midazolam).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Lee 2015	21	40	34	40	65.7%	0.20 [0.07, 0.57]	
Yoshio 2019	2	65	27	99	34.3%	0.08 [0.02, 0.37]	
Total (95% CI)		**105**		**139**	**100.0%**	**0.15 [0.06, 0.35]**	
Total events	23		61				

Heterogeneity: Tau² = 0.00; Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 4.35 (P < 0.0001)

Favours Dex+Midazolam Favours Control

Figure 21: Bradycardia (Dex + Midazolam).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Iwagami 2023	4	155	0	132	28.3%	7.87 [0.42, 147.56]	
Lee 2015	5	40	1	40	41.9%	5.57 [0.62, 50.03]	
Yoshio 2019	23	65	0	99	29.9%	110.04 [6.53, 1853.58]	
Total (95% CI)		**260**		**271**	**100.0%**	**14.97 [2.44, 91.68]**	
Total events	32		1				

Heterogeneity: Tau² = 0.79; Chi² = 2.87, df = 2 (P = 0.24); I² = 30%
Test for overall effect: Z = 2.93 (P = 0.003)

Favours Dex+Midazolam Favours

Figure 22: Hypoxia (Dex + Midazolam).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Iwagami 2023	17	155	8	132	33.5%	1.91 [0.80, 4.58]
Lee 2015	7	40	11	40	28.8%	0.56 [0.19, 1.63]
Yoshio 2019	15	65	38	99	37.8%	0.48 [0.24, 0.97]
Total (95% CI)		260		271	100.0%	0.80 [0.33, 1.94]
Total events	39		57			

Heterogeneity: Tau² = 0.41; Chi² = 6.19, df = 2 (P = 0.05); I² = 68%
Test for overall effect: Z = 0.50 (P = 0.62)

Figure 23: Bleeding (Dex + Midazolam).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Iwagami 2023	0	155	1	132	17.2%	0.28 [0.01, 6.98]
Lee 2015	3	40	6	40	82.8%	0.46 [0.11, 1.98]
Total (95% CI)		195		172	100.0%	0.42 [0.11, 1.60]
Total events	3		7			

Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 1.27 (P = 0.20)

Figure 24: Perforation (Dex + Midazolam).

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Iwagami 2023	0	155	7	132	49.4%	0.05 [0.00, 0.95]
Lee 2015	1	40	1	40	50.6%	1.00 [0.06, 16.56]
Total (95% CI)		195		172	100.0%	0.24 [0.01, 4.13]
Total events	1		8			

Heterogeneity: Tau² = 2.17; Chi² = 2.03, df = 1 (P = 0.15); I² = 51%
Test for overall effect: Z = 0.99 (P = 0.32)

Tables Legend:

Author	Country	Study design	Age mean /(SD)		Intervention(t/control)	Procedure location	Size of lesion mean /(SD)	
			Cases	control			Cases	control
Ashikari 2021	Japan	RCT	21.25 (8.29)	22.97 (12.78)	propofol plus dexmedetomidine; propofol alone.	superficial esophageal cancers	68.86 (30.99)	8 (24.24)
Iwagami 2023	Japan	retrospective COHORT	NA	NA	Midazolam and pethidine hydrochloride + DEX; Midazolam and pethidine hydrochloride	colorectal lesions	64.4(38.2)	85 (55)
Kim 2015	Korea	RCT	62.8 (8.5)	65.1 (10.2)	Dexmedetomidine-remifentanil (DR); propofol-remifentanil (PR)	Esophagus	62.9 (12.3)	10 (34.5)
Kinugasa 2018	Japan	RCT	22.4 (4.3)	22.5 (2.77)	Dex + Pethidine; Pethidine	Colorectal	67.9 (33.8)	21 (52%)
Lee 2015	Korea	RCT	23.79 (2.70)	24.32 (2.07)	dexmedetomidine (DEX) with on-demand MDZ ; MDZ alone	Gastric Tumor	15	22.5
Luo 2023	China	RCT	57 (7)	55.8 (7.5)	Dex bolus + maintenance intraop; Normal saline	Stomach - gastric	3.4 (1.2)	2.8 (1.3)

Table 1: Baseline Characteristics of The Included Studies.

| Nonaka 2016 | Japan | Retrospective | 66.3 (7.7) | 68.4 (8.5) | Combination of propofol and dex; Benzodiazepines | Esophagus | 40.1 (12) | 40.8 (15.2) |
| Yoshio 2019 | Japan | Prospective confrmatory single arm | 67.7 (5.7) | N/A | Bolus midazolam and pethidine + dex infusion; Midazolam and pethidine boluses | Esophagus | 17.3 (8.5) | N/A |